Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, has been selected as a late breaking abstract to present Phase II interim data ...

SHANGHAI and SANTA BARBARA, Calif., Dec. 17, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in next-generation RNAi medicines, today announced the submission of RN5681 to the Australian Human ...

This deal adds two more siRNA candidates to GSK’s pipeline, which the company is looking to expand as it looks to offset the ...

SHANGHAI and BOSTON, Sept. 15, 2025 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced that the ...

株式会社レトリバ（本社：東京都新宿区、代表取締役 田口琢也）は、かねてよりAI技術をバイオ領域で活用してきました。高速塩基配列検索ソフトウェア 「GGGenome(ゲゲゲノム)※1パッケージ版」 は核酸医薬品の安全性評価において信頼と実績もっています。

Vial's INHBE siRNA is a first-in-class, liver-targeted (GalNAc-conjugated) siRNA therapy that silences INHBE and its gene product, Activin E Leading key opinion leaders (KOLs) Drs. Jason Fung, Scott ...

German pharma giant Bayer AG BAYRY has entered into a collaboration and global licensing agreement with Soufflé Therapeutics to develop a heart-targeted small interfering RNA (siRNA) therapy in a move ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Silence Therapeutics has unveiled ...

SHANGHAI and BOSTON, Nov. 6, 2025 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced it will ...

Researchers from E-Therapeutics plc presented preclinical data for ETX-312, a GalNAc-conjugated short interfering RNA (siRNA), produced using the Galomic platform and being developed for the treatment ...